Skip to main content

Table 1 Demographic and baseline characteristics

From: Circulating tumor cells in patients undergoing androgen deprivation therapy with versus without cryosurgery for metastatic prostate cancer: a retrospective analysis

 

ADT alone, n = 23

ADT + cryosurgery, n = 20

p

Age (years), mean ± SD

68.7 ± 7.2

70.3 ± 7.5

0.479

 ≤60, n (%)

3 (13.0%)

2 (10%)

0.716

 60‑70, n (%)

14 (60.9%)

12 (60%)

 > 70, n (%)

6 (26.1%)

6 (30%)

PSA (ng/ml), mean ± SD

84.16 ± 27.45

84.83 ± 31.77

0.074

Biopsy Gleason score, n (%)

 ≤ 6

1 (4.3%)

2 (10%)

0.615

 7

8 (34.8%)

7 (35%)

 ≥ 8

14 (60.9%)

11 (55%)

Prostate volume (ml), mean ± SD

42.00 ± 3.73

42.30 ± 4.24

0.806

Clinical T stage, n (%)

 ≤cT2b

8 (34.8%)

5 (25%)

0.555

 cT2c

10 (43.5%)

10 (50%)

 cT3a

5 (21.7%)

5 (25%)

Lymph nodes status, n (%)

 N0

18 (78.3%)

15 (75%)

0.801

 N1

5 (21.7%)

5 (25%)

Bone metastases count, n (%)

 ≤ 3

10 (43.5%)

11 (55%)

0.451

 > 3

13 (56.5%)

9 (45%)

CTCs count, median (IQR)

6 (3‑7)

4 (3‑6)

0.475

  1. ADT androgen deprivation therapy, CTC circulating tumor cell, IQR interquartile range, PSA prostate specific antigen, SD standard deviation